- Conditions
- Schizophrenia
- Interventions
- Zicronapine open-label lead-in 10 mg daily, Zicronapine 10 mg daily, Zicronapine 20 mg once weekly, Zicronapine 30 mg once weekly, Zicronapine 45 mg once weekly
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 4
- States / cities
- Garden Grove, California • National City, California • San Diego, California + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,650
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Alcoholism, Dual Diagnosis
- Interventions
- Risperidone + Desipramine
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Worcester, Massachusetts • Grand Rapids, Michigan • Lebanon, New Hampshire + 1 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
- Interventions
- Pramlintide, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders, Psychotic Disorders, Psychotic Mood Disorders, Psychoses, Affective, Psychosis Nos/Other, Schizophrenia Spectrum and Other Psychotic Disorders
- Interventions
- BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm, BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Psychotic Disorders, Bipolar Disorder, Unemployment
- Interventions
- Adapted Motivational Interviewing (AMI), Support and Education for Recovery (SER)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Bedford, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- KarXT, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 102
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 71 more
- Conditions
- Treatment-resistant Schizophrenia
- Interventions
- Insightec Exablate Neuro MR-guided focused ultrasound transducer
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia With Impulsivity
- Interventions
- Brexpiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania, Manic State
- Interventions
- Pentazocine, Lorazepam
- Drug
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Schizophrenia
- Interventions
- Minocycline, Placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Catonsville, Maryland
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Interventions
- Cognitive-Behavior Therapy, Standard Psychiatric Treatment
- Behavioral · Other
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia
- Interventions
- Self-management therapy
- Behavioral
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 15 Years to 19 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Schizophrenia
- Interventions
- LTX-001 once daily, Placebo, LTX-001 twice daily
- Drug
- Lead sponsor
- Leal Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Los Alamitos, California • DeLand, Florida + 6 more
- Conditions
- Schizophrenia, Nicotine Dependence
- Interventions
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Schizophrenia
- Interventions
- 10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Schizophrenia
- Interventions
- Iloperidone
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Gaithersburg, Maryland • Marlton, New Jersey
- Conditions
- Schizophrenia
- Interventions
- NBI-1117568, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Culver City, California • Garden Grove, California + 4 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, bitopertin [RO4917838]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 21
- States / cities
- Carson, California • Oceanside, California • San Diego, California + 17 more
- Conditions
- Schizophrenia
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 6 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Schizophrenia
- Interventions
- CX516 (Ampakine)
- Drug
- Lead sponsor
- North Suffolk Mental Health Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 105 participants
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia
- Interventions
- Placebo, Cariprazine, Risperidone
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 18
- States / cities
- Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Interventions
- Not listed
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 14 Years to 62 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Schizophrenia
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Schizophrenia
- Interventions
- ITI-007, Risperidone, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 8 more